Dyadic International vs Evogene
DYAI and EVGN side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DYAI and EVGN compare
Dyadic International grew revenue faster over the last twelve months (−8.0% versus −30.9% for Evogene).
Dyadic International keeps more of each dollar of sales as profit, with a net margin of −200% compared with −220% at Evogene.
Dyadic International scores higher on the StockData Score (7 against 3 for Evogene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DYAI | EVGN |
|---|---|---|
| Size and price | ||
| Market cap | $14.1M | – |
| Share price | $0.388 | $0.395 |
| Change, 1 year | −61.2% | −66.6% |
| Change, 5 years | −89.9% | −98.1% |
| Beta (5Y) | 1.21 | 1.04 |
| Employees | 5 | 78 |
| StockData Score | ||
| Total score | 7 (better) | 3 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.7× | – |
| Growth | ||
| Revenue growth (TTM) | −8.0% (better) | −30.9% |
| Revenue growth, 5Y average | 14.0% | 29.9% (better) |
| Profitability | ||
| Gross margin | 16.2% (better) | −6.3% |
| Operating margin | −195% (better) | −364% |
| Net margin | −200% (better) | −220% |
| FCF margin | – | −354% |
| Financial health | ||
| Interest coverage | – | −7.3× |
| Current ratio | 1.65 | 3.57 (better) |
| Altman Z-score | −22.64 | – |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 12.7% | 3.2% |
| Held by insiders | 28.0% | 50.7% |
| Insider net buying, 12 months | −$125K | $695K (better) |
| Short interest, % of float | 0.32% | 1.6% |
Go deeper
- DYAI stock overview
- DYAI income statement
- DYAI valuation and score
- EVGN stock overview
- EVGN income statement
- EVGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.